Docoh
Loading...

TENX Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway.

Company profile

Ticker
TENX
Exchange
CEO
Anthony DiTonno
Employees
Incorporated
Location
Fiscal year end
Former names
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC
SEC CIK
IRS number
262593535

TENX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 3.54M 3.54M 3.54M 3.54M 3.54M 3.54M
Cash burn (monthly) 904.48K 68.49K (positive/no burn) (positive/no burn) 1.07M 818.58K
Cash used (since last report) 2.52M 190.87K n/a n/a 2.99M 2.28M
Cash remaining 1.02M 3.35M n/a n/a 544.52K 1.26M
Runway (months of cash) 1.1 48.9 n/a n/a 0.5 1.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
11 Jun 21 Michael H. Davidson Common Stock Grant Aquire A No No 0 512,000 0 606,645
11 Jun 21 Michael H. Davidson Series B Preferred Stock Common Stock Option exercise Dispose M No No 0 512 0 0
11 Jun 21 Stuart Rich Common Stock Option exercise Aquire M No No 0 3,581,000 0 4,243,517
11 Jun 21 Stuart Rich Series B Preferred Stock Common Stock Option exercise Dispose M No No 0 3,581 0 0
11 Jun 21 Doogan Declan Common Stock Option exercise Aquire M No No 0 3,070,000 0 3,637,871
11 Jun 21 Doogan Declan Series B Preferred Stock Common Stock Option exercise Dispose M No No 0 3,070 0 0
10 Jun 21 Michael H. Davidson Stock Option Common Stock Grant Aquire A No No 2 6,250 12.5K 6,250
10 Jun 21 Doogan Declan Stock Option Common Stock Grant Aquire A No No 2 6,250 12.5K 6,250
10 Jun 21 Mitchum James P. Stock Option Common Stock Grant Aquire A No No 2 5,000 10K 5,000
10 Jun 21 Proehl Gerald T Stock Option Common Stock Grant Aquire A No No 2 5,000 10K 5,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

25.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 25 2 +1150.0%
Opened positions 24 1 +2300.0%
Closed positions 1 25 -96.0%
Increased positions 1 0 NEW
Reduced positions 0 1 EXIT
13F shares
Current Prev Q Change
Total value 7.21M 2.24M +222.0%
Total shares 3.8M 1.2M +215.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Armistice Capital 2.02M $3.84M NEW
Renaissance Technologies 747.83K $1.42M +75.1%
BLK Blackrock 599.1K $1.14M NEW
Vanguard 177.89K $338K NEW
Dimensional Fund Advisors 60.41K $115K NEW
Financial Advisory Service 58.33K $111K NEW
Geode Capital Management 52.3K $99K NEW
AMP Ameriprise Financial 30K $57K NEW
NTRS Northern Trust 17.02K $32K NEW
Citadel Advisors 15.96K $30K NEW
Largest transactions
Shares Bought/sold Change
Armistice Capital 2.02M +2.02M NEW
Hudson Bay Capital Management 0 -777.2K EXIT
BLK Blackrock 599.1K +599.1K NEW
Renaissance Technologies 747.83K +320.8K +75.1%
Vanguard 177.89K +177.89K NEW
Dimensional Fund Advisors 60.41K +60.41K NEW
Financial Advisory Service 58.33K +58.33K NEW
Geode Capital Management 52.3K +52.3K NEW
AMP Ameriprise Financial 30K +30K NEW
NTRS Northern Trust 17.02K +17.02K NEW

Financial report summary

?
Competition
CytokineticsGossamer Bio
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abdominal, absorbed, addressed, adjunct, advice, affirmative, amino, animal, appetite, ATP, automatically, binding, bioavailability, biological, Breakthrough, call, called, cancer, cardioprotective, cascade, causal, central, characterize, CML, confounded, consideration, contractility, convene, conventional, cytochrome, Davidson, Declan, demand, denied, Deregulation, diarrhea, differentiation, discovered, discovery, distention, diverse, Doogan, Dr, dramatic, earlier, edema, employment, enzyme, explored, external, factor, FC, February, Finnish, fluid, formula, gastric, Gleevec, growth, halt, headache, human, imatinib, Imputed, indemnification, inhibit, inhibiting, inhibitor, innovative, inotropic, intangible, intolerance, invited, kinase, largely, led, leukemia, liver, lock, marketplace, Med, mediated, merge, merged, metabolism, metabolized, mitochondrial, morbidity, mortality, multiple, muscle, myeloid, myelosuppression, nausea, NDA, negotiated, noncancer, Opening, organization, orphan, outpatient, overexpressed, PAH, pathway, PDGF, PDGFRA, perfusion, PH, PHPM, PHPrecisionMed, platelet, play, potassium, power, practicable, Precision, preload, produce, progression, promptly, proposal, proposed, protein, protocol, pyrimidine, qualitatively, rare, rash, recognition, recommend, regression, regularly, remeasured, remeasurement, retention, revolutionized, Rich, satisfaction, Secretary, show, showing, signaling, significantly, size, smooth, solicit, sponsor, sponsored, stabilizing, stimuli, Stuart, subpart, successfully, surgery, surrogate, symptomatic, therapy, tissue, tolerability, tolerated, transition, triple, troponin, tyrosine, vasculature, vasodilatory, vomiting, waiver, withdraw, world
Removed: acceptable, acting, analyzing, applying, arbitral, attendance, audit, belief, bid, bond, Calculation, certify, chain, civil, clarity, compliance, confidence, consecutive, consume, controversy, correct, coverage, criminal, declaration, delist, delisting, Department, discouraging, disruption, economy, epidemic, evaluating, exceed, exercised, expire, faith, False, federal, fewer, forgiven, good, government, governmental, gradient, harm, health, hearing, inaccurate, industry, ineligible, initially, intend, interpretation, interruption, Linkbase, liquidity, listed, listing, lose, matter, media, minimize, minimum, negatively, notification, objective, operation, precautionary, predict, preemption, presently, publicity, qualification, qualifying, regain, reimburse, rejected, rely, remotely, repay, reputation, request, requested, requirement, requiring, resulted, risk, RV, satisfied, satisfy, sensitizer, situation, supply, suspending, temporarily, tolled, tribunal, violation, work